1. In Vivo
  2. >>Innovation

Overcoming Roadblocks: Innovations And Collaborations In Cell And Gene Therapy

 
• By Fenwick Eckhardt

Bad actors, lack of funding and skilled workforce shortages threaten to hinder the growth of cell and gene therapies. To unleash the transformative power of cell and gene therapies requires the concerted effort of the entire CGT community.  

Traffic cone and arrow
• Source: Shutterstock

Despite the groundbreaking potential of cell and gene therapy (CGT), and like many other new technologies, the CGT space faces significant challenges that hinder its progress. At the June 2023 International Society for the Cell and Gene Therapies (ISCT) conference in Paris, committee members, regulators, academics and industry personnel gathered to discuss the primary obstacles impeding the advancement of this cutting-edge field.

At the forefront of the 2023 ISCT Conference was the excitement for the Global Regulators Summit, which took place on...

More from Innovation

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.